Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VINCENT M BIVINS

Allopathic & Osteopathic Physicians Urology

NPI
1609850619
CMS profile
26974
Location
HOMEWOOD, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$29,566.15

92 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VINCENT M BIVINS

NPI 1609850619 · CMS profile ID 26974

Allopathic & Osteopathic Physicians / Urology

HOMEWOOD, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609850619?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VINCENT M BIVINS, NPI 1609850619, CMS profile ID 26974. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609850619?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). VINCENT M BIVINS, NPI 1609850619, CMS profile ID 26974. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609850619?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
VINCENT M BIVINS, NPI 1609850619, CMS profile ID 26974, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1609850619?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

92 matching records · $29,566.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 92 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–92 of 92.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Becton, Dickinson and Company $15.1005/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232248951 CMS
Olympus America Inc. $27.9905/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223084226 CMS
AVYXA PHARMA, LLC $40.0005/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240102103 CMS
AVYXA PHARMA, LLC $65.7105/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240102105 CMS
AVYXA PHARMA, LLC $117.7505/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240102127 CMS
AVYXA PHARMA, LLC $414.9605/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240102129 CMS
AVYXA PHARMA, LLC $557.1305/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240102131 CMS
AVYXA PHARMA, LLC $2,000.0005/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1240102133 CMS
Janssen Biotech, Inc. $17.3805/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174400304 CMS
Blue Earth Diagnostics $108.1405/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252661391 CMS
Novartis Pharmaceuticals Corporation $119.5905/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200094330 CMS
Dendreon Pharmaceuticals LLC $27.4305/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244998394 CMS
Dendreon Pharmaceuticals LLC $66.6505/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244998396 CMS
Endo USA, Inc. $21.5904/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201195731 CMS
Dendreon Pharmaceuticals LLC $49.8704/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244998392 CMS
Dendreon Pharmaceuticals LLC $111.1904/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244998390 CMS
TOLMAR, INC. $23.9604/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237013174 CMS
Merck Sharp & Dohme LLC $22.9504/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238312468 CMS
IMMUNITYBIO, INC. $19.2904/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233174138 CMS
Janssen Biotech, Inc. $14.9604/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174400058 CMS
Dendreon Pharmaceuticals LLC $173.3203/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244998382 CMS
Dendreon Pharmaceuticals LLC $3,150.0003/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244998384 CMS
Dendreon Pharmaceuticals LLC $25.0003/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244998386 CMS
Dendreon Pharmaceuticals LLC $348.6003/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244998388 CMS
Janssen Biotech, Inc. $34.1703/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174400316 CMS
Endo USA, Inc. $27.2303/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201195727 CMS
Dendreon Pharmaceuticals LLC $1,050.0003/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244998380 CMS
Merck Sharp & Dohme LLC $26.7403/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238136981 CMS
Ferring Pharmaceuticals Inc. $18.5403/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242059036 CMS
Antares Pharma, Inc. $20.9803/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235882107 CMS
Ferring Pharmaceuticals Inc. $24.7203/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242059034 CMS
Dendreon Pharmaceuticals LLC $132.5403/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244998378 CMS
Sumitomo Pharma America, Inc. $17.2202/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176604758 CMS
UROGEN PHARMA, INC. $28.1902/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244832294 CMS
IMMUNITYBIO, INC. $18.8602/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233172484 CMS
Olympus America Inc. $29.6202/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223084224 CMS
Laborie Medical Technologies Corp. $21.7202/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250404136 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.0402/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225468711 CMS
Janssen Biotech, Inc. $14.8201/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174399356 CMS
Sumitomo Pharma America, Inc. $23.8001/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176604755 CMS
PFIZER INC. $17.8501/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231250336 CMS
AstraZeneca Pharmaceuticals LP $2,025.0001/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206614925 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,437.27 48
PY2020 $11,386.85 25
PY2021 $8,796.66 54
PY2022 $9,492.78 56
PY2023 $20,836.18 76
PY2024 $32,388.56 103
PY2025 $29,566.15 92

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $564,490.40 34
PY2024 Principal investigator $422,764.76 18
PY2023 Principal investigator $103,140.80 7
PY2022 Principal investigator $44,246.65 8
PY2021 Principal investigator $10,027.93 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $19,460.00 12/26/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397193
Principal investigator 1 Janssen Research & Development, LLC $4,032.00 12/01/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397144
Principal investigator 1 Janssen Research & Development, LLC $10,833.00 11/27/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397200
Principal investigator 1 Janssen Research & Development, LLC $25,647.00 11/17/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397070
Principal investigator 1 Janssen Research & Development, LLC $32,955.00 11/17/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397091
Principal investigator 1 Janssen Research & Development, LLC $20,058.00 11/17/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397180
Principal investigator 1 Janssen Research & Development, LLC $11,571.00 11/12/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397113
Principal investigator 1 Janssen Research & Development, LLC $29,384.44 11/03/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397156
Principal investigator 1 Myriad Genetic Laboratories, Inc. $9,715.08 09/30/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
URO-013 No dispute reported 06/30/2026 1245407246
Principal investigator 1 PFIZER INC. $1,669.75 09/16/2025 Non-covered Recipient Entity
Urology Centers of Alabama
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228759418
Principal investigator 1 Janssen Research & Development, LLC $14,503.00 09/05/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397024
Principal investigator 1 Janssen Research & Development, LLC $3,857.00 07/28/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397106
Principal investigator 1 Janssen Research & Development, LLC $11,571.00 07/07/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397028
Principal investigator 1 PFIZER INC. $800.00 06/24/2025 Non-covered Recipient Entity
Urology Centers of Alabama
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228760216
Principal investigator 1 Janssen Research & Development, LLC $18,698.00 06/23/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397137
Principal investigator 1 Janssen Research & Development, LLC $25,684.44 06/09/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397050
Principal investigator 1 Janssen Research & Development, LLC $26,999.00 06/09/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397149
Principal investigator 1 PFIZER INC. $1,300.00 05/30/2025 Non-covered Recipient Entity
Urology Centers of Alabama
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228772976
Principal investigator 1 Janssen Research & Development, LLC $18,298.00 05/19/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397058
Principal investigator 1 Janssen Research & Development, LLC $7,714.00 04/28/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397076
Principal investigator 1 Janssen Research & Development, LLC $18,298.00 04/10/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397169
Principal investigator 1 Janssen Research & Development, LLC $3,857.00 04/03/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397187
Principal investigator 1 PFIZER INC. $1,008.24 04/01/2025 Non-covered Recipient Entity
Urology Centers of Alabama
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228760165
Principal investigator 1 PFIZER INC. $46,207.89 04/01/2025 Non-covered Recipient Entity
Urology Centers of Alabama
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228770178
Principal investigator 1 Myriad Genetic Laboratories, Inc. $5,395.00 03/31/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
URO-013 No dispute reported 06/30/2026 1245407019
Principal investigator 1 PFIZER INC. $24,034.00 03/22/2025 Non-covered Recipient Entity
Urology Centers of Alabama
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228778473
Principal investigator 1 Janssen Research & Development, LLC $6,614.00 03/07/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397086
Principal investigator 1 Janssen Research & Development, LLC $53,331.44 03/03/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397131
Principal investigator 1 PFIZER INC. $853.20 02/28/2025 Non-covered Recipient Entity
Urology Centers of Alabama
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228725280
Principal investigator 1 PFIZER INC. $1,128.60 02/28/2025 Non-covered Recipient Entity
Urology Centers of Alabama
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228734510
Principal investigator 1 Janssen Research & Development, LLC $35,857.00 02/10/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397045
Principal investigator 1 Janssen Research & Development, LLC $32,045.00 01/27/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397125
Principal investigator 1 Janssen Research & Development, LLC $37,915.32 01/20/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397039
Principal investigator 1 Janssen Research & Development, LLC $3,196.00 01/20/2025 Non-covered Recipient Entity
UROLOGY CENTERS OF ALABAMA
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175397062